Lilly's Zepbound Outperforms Wegovy In Phase 3b Trial For Weight Reduction
12/5 03:46
(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during the Phase 3b open-label clinical trial....